ceftriaxone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 564 73384-59-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ceftriaxone sodium hydrate
  • ceftriaxone
  • biotrakson
  • rocefin
  • rocephalin
  • rophex
  • ceftriaxone sodium
A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.
  • Molecular weight: 554.57
  • Formula: C18H18N8O7S3
  • CLOGP: 0.02
  • LIPINSKI: 2
  • HAC: 15
  • HDO: 4
  • TPSA: 208.98
  • ALOGS: -3.72
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g P
2 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 400 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 46 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 120.27 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.22 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1984 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 715.09 52.54 170 2819 5348 2349748
Toxic epidermal necrolysis 427.86 52.54 101 2888 3043 2352053
Acute kidney injury 395.70 52.54 157 2832 27965 2327131
Rash 365.94 52.54 186 2803 59372 2295724
Cholelithiasis 352.55 52.54 98 2891 5705 2349391
Acute generalised exanthematous pustulosis 309.71 52.54 69 2920 1589 2353507
Pyrexia 292.65 52.54 155 2834 53553 2301543
Hepatitis 268.86 52.54 81 2908 6256 2348840
Anaphylactic shock 262.92 52.54 73 2916 4213 2350883
Erythema 247.19 52.54 109 2880 25050 2330046
Jarisch-Herxheimer reaction 246.22 52.54 37 2952 64 2355032
Pruritus 243.93 52.54 128 2861 43212 2311884
Drug ineffective 235.72 52.54 170 2819 101454 2253642
Haemolytic anaemia 227.42 52.54 55 2934 1826 2353270
Stevens-Johnson syndrome 226.97 52.54 65 2924 4194 2350902
Urticaria 221.85 52.54 100 2889 24161 2330935
Multiple organ dysfunction syndrome 217.27 52.54 72 2917 7569 2347527
Dyspnoea 208.38 52.54 143 2846 78590 2276506
Tubulointerstitial nephritis 189.10 52.54 50 2939 2388 2352708
Pseudocholelithiasis 183.75 52.54 24 2965 0 2355096
Rash maculo-papular 170.09 52.54 52 2937 4200 2350896
Factor V inhibition 169.76 52.54 24 2965 19 2355077
Hypotension 160.14 52.54 88 2901 32348 2322748
Condition aggravated 155.77 52.54 86 2903 31893 2323203
Pneumonia 155.19 52.54 100 2889 49196 2305900
Drug hypersensitivity 152.71 52.54 97 2892 46546 2308550
Anaphylactic reaction 152.65 52.54 59 2930 9646 2345450
Postrenal failure 146.36 52.54 22 2967 38 2355058
Clostridium difficile colitis 143.98 52.54 39 2950 2040 2353056
Tachycardia 138.24 52.54 64 2925 16345 2338751
Thrombocytopenia 134.86 52.54 66 2923 19065 2336031
Eosinophilia 134.56 52.54 40 2949 2930 2352166
Agranulocytosis 132.50 52.54 41 2948 3441 2351655
Maternal exposure during pregnancy 131.54 52.54 60 2929 14803 2340293
Status epilepticus 128.22 52.54 37 2952 2441 2352655
Haemophagocytic lymphohistiocytosis 119.87 52.54 31 2958 1352 2353744
Septic shock 118.44 52.54 45 2944 7009 2348087
Drug interaction 116.56 52.54 69 2920 29094 2326002
Neutropenia 107.62 52.54 59 2930 21489 2333607
Sepsis 104.58 52.54 55 2934 18433 2336663
Angioedema 100.62 52.54 42 2947 8354 2346742
Drug resistance 100.24 52.54 31 2958 2593 2352503
Hypersensitivity 94.66 52.54 56 2933 23537 2331559
Drug-induced liver injury 93.67 52.54 32 2957 3667 2351429
Anaemia 93.29 52.54 64 2925 34728 2320368
Diarrhoea 92.94 52.54 92 2897 83472 2271624
Cardiac arrest 91.82 52.54 47 2942 14883 2340213
Pancytopenia 91.18 52.54 43 2946 11409 2343687
Hydronephrosis 88.77 52.54 24 2965 1243 2353853
Haemolysis 88.21 52.54 23 2966 1035 2354061
Respiratory failure 87.30 52.54 44 2945 13484 2341612
Leukocytosis 86.91 52.54 30 2959 3546 2351550
Vomiting 85.48 52.54 82 2907 71520 2283576
Cholecystitis 83.59 52.54 26 2963 2214 2352882
Cholangitis 82.57 52.54 21 2968 855 2354241
Hypoxia 80.85 52.54 33 2956 6194 2348902
Dermatitis bullous 80.20 52.54 23 2966 1481 2353615
Abdominal pain 79.97 52.54 58 2931 34316 2320780
Encephalopathy 76.16 52.54 29 2960 4532 2350564
Laryngeal stenosis 75.74 52.54 13 2976 68 2355028
Symmetrical drug-related intertriginous and flexural exanthema 73.37 52.54 12 2977 44 2355052
Influenza B virus test positive 72.45 52.54 11 2978 21 2355075
Choreoathetosis 71.75 52.54 14 2975 162 2354934
Blister 71.57 52.54 31 2958 6740 2348356
Cholestasis 70.66 52.54 26 2963 3695 2351401
Disseminated intravascular coagulation 69.54 52.54 25 2964 3325 2351771
Clostridium difficile infection 69.26 52.54 24 2965 2866 2352230
Lip oedema 68.53 52.54 18 2971 833 2354263
Anuria 67.33 52.54 21 2968 1803 2353293
Dermatitis exfoliative 66.26 52.54 19 2970 1222 2353874
Alanine aminotransferase increased 66.07 52.54 37 2952 13995 2341101
Enterococcal infection 65.86 52.54 17 2972 734 2354362
Exposure during pregnancy 64.24 52.54 45 2944 25174 2329922
Renal failure 63.87 52.54 39 2950 17310 2337786
Acute respiratory distress syndrome 62.49 52.54 23 2966 3269 2351827
Linear IgA disease 62.00 52.54 14 2975 340 2354756
Rash erythematous 61.97 52.54 27 2962 5949 2349147
Depressed level of consciousness 61.86 52.54 29 2960 7575 2347521
Autoimmune haemolytic anaemia 61.39 52.54 16 2973 718 2354378
Pseudomembranous colitis 60.78 52.54 15 2974 539 2354557
Unresponsive to stimuli 60.42 52.54 25 2964 4851 2350245
Klebsiella infection 59.69 52.54 16 2973 801 2354295
Aspartate aminotransferase increased 58.67 52.54 33 2956 12579 2342517
Respiratory disorder 58.11 52.54 23 2966 3981 2351115
Langerhans' cell histiocytosis 56.95 52.54 10 2979 61 2355035
Loss of consciousness 56.13 52.54 37 2952 18730 2336366
Respiratory distress 55.88 52.54 24 2965 5105 2349991
Premature delivery 55.77 52.54 21 2968 3179 2351917
Altered state of consciousness 55.41 52.54 22 2967 3838 2351258
Respiratory acidosis 54.92 52.54 15 2974 806 2354290
Shock 54.63 52.54 22 2967 3982 2351114
Hepatocellular injury 54.36 52.54 22 2967 4033 2351063
Hepatitis cholestatic 54.18 52.54 16 2973 1141 2353955

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Postrenal failure 491.60 45.73 77 2872 93 1743739
Drug reaction with eosinophilia and systemic symptoms 378.75 45.73 112 2837 4958 1738874
Acute kidney injury 373.75 45.73 186 2763 34758 1709074
Cholelithiasis 359.20 45.73 97 2852 3068 1740764
Jarisch-Herxheimer reaction 326.63 45.73 56 2893 158 1743674
Drug ineffective 276.69 45.73 189 2760 63612 1680220
Rash 274.63 45.73 157 2792 38536 1705296
Pruritus 260.27 45.73 128 2821 23094 1720738
Hydronephrosis 254.34 45.73 62 2887 1283 1742549
Pyrexia 243.17 45.73 155 2794 46245 1697587
Anaphylactic reaction 232.77 45.73 81 2868 6032 1737800
Toxic epidermal necrolysis 228.59 45.73 64 2885 2307 1741525
Ureterolithiasis 227.12 45.73 45 2904 332 1743500
Anaphylactic shock 202.83 45.73 61 2888 2838 1740994
Urticaria 191.01 45.73 85 2864 12156 1731676
Rash maculo-papular 184.06 45.73 60 2889 3643 1740189
Acute generalised exanthematous pustulosis 158.59 45.73 41 2908 1081 1742751
Erythema 157.80 45.73 78 2871 14110 1729722
Drug-induced liver injury 154.97 45.73 51 2898 3186 1740646
Anuria 150.62 45.73 44 2905 1844 1741988
Neutropenia 144.74 45.73 80 2869 18180 1725652
Dyspnoea 143.32 45.73 118 2831 51941 1691891
Hypotension 139.69 45.73 93 2856 29561 1714271
Tubulointerstitial nephritis 139.15 45.73 46 2903 2912 1740920
Haemolytic anaemia 133.68 45.73 40 2909 1822 1742010
Pseudocholelithiasis 128.99 45.73 18 2931 0 1743832
Immune reconstitution inflammatory syndrome 127.51 45.73 37 2912 1512 1742320
Cholestasis 125.70 45.73 45 2904 3620 1740212
Flank pain 119.68 45.73 32 2917 963 1742869
Drug hypersensitivity 116.24 45.73 65 2884 15070 1728762
Thrombocytopenia 110.53 45.73 71 2878 21178 1722654
Diarrhoea 109.73 45.73 103 2846 53749 1690083
Factor V inhibition 106.45 45.73 18 2931 45 1743787
Haemolysis 105.84 45.73 30 2919 1125 1742707
Hepatocellular injury 104.50 45.73 38 2911 3193 1740639
Vomiting 101.26 45.73 85 2864 38230 1705602
Condition aggravated 101.00 45.73 67 2882 21083 1722749
Crying 94.33 45.73 29 2920 1446 1742386
Stevens-Johnson syndrome 88.53 45.73 34 2915 3323 1740509
Hypersensitivity 85.98 45.73 47 2902 10397 1733435
Angioedema 83.75 45.73 45 2904 9619 1734213
Drug resistance 82.63 45.73 32 2917 3198 1740634
Hepatitis 82.19 45.73 36 2913 4919 1738913
Respiratory failure 81.63 45.73 51 2898 14454 1729378
Clostridium difficile infection 80.91 45.73 27 2922 1754 1742078
Eosinophilia 79.90 45.73 32 2917 3495 1740337
Agranulocytosis 76.03 45.73 31 2918 3545 1740287
Cardiac arrest 74.83 45.73 50 2899 15880 1727952
Multiple organ dysfunction syndrome 74.42 45.73 41 2908 9201 1734631
Disseminated intravascular coagulation 72.31 45.73 30 2919 3584 1740248
Pancreatitis acute 72.03 45.73 31 2918 4056 1739776
Alanine aminotransferase increased 71.16 45.73 44 2905 12234 1731598
Blood urea increased 70.97 45.73 32 2917 4679 1739153
Tachycardia 70.02 45.73 44 2905 12584 1731248
Septic shock 68.11 45.73 37 2912 8072 1735760
Clostridium difficile colitis 67.66 45.73 23 2926 1581 1742251
Pathogen resistance 63.68 45.73 20 2929 1069 1742763
Abdominal pain 63.55 45.73 51 2898 21439 1722393
Oxygen saturation decreased 62.30 45.73 31 2918 5644 1738188
Oral candidiasis 60.07 45.73 20 2929 1289 1742543
Altered state of consciousness 59.89 45.73 26 2923 3471 1740361
Choreoathetosis 59.54 45.73 13 2936 160 1743672
Sphincter of Oddi dysfunction 59.13 45.73 10 2939 25 1743807
Blood creatinine increased 58.87 45.73 41 2908 13905 1729927
Blood alkaline phosphatase increased 58.87 45.73 29 2920 5166 1738666
Unresponsive to stimuli 55.93 45.73 27 2922 4602 1739230
Treatment failure 54.17 45.73 26 2923 4375 1739457
Renal impairment 53.84 45.73 37 2912 12277 1731555
Aspartate aminotransferase increased 53.46 45.73 35 2914 10721 1733111
Drug interaction 51.94 45.73 51 2898 27907 1715925
Erythema multiforme 50.75 45.73 19 2930 1727 1742105
Pseudomembranous colitis 49.82 45.73 14 2935 507 1743325
Renal failure 49.78 45.73 43 2906 19974 1723858
Nocardiosis 49.46 45.73 14 2935 521 1743311
Liver injury 49.37 45.73 19 2930 1863 1741969
Pancytopenia 47.00 45.73 33 2916 11324 1732508
Jaundice 46.31 45.73 26 2923 6036 1737796

Pharmacologic Action:

SourceCodeDescription
ATC J01DD04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD54 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD63 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:88188 drug allergen
FDA EPC N0000175488 Cephalosporin Antibacterial
FDA CS M0003827 Cephalosporins

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Gonococcal meningitis indication 151004
Streptococcal meningitis indication 4510004 DOID:11574
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Staphylococcal meningitis indication 12166008
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Streptococcal septicemia indication 29577008
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Gonorrhea of rectum indication 42746002
Gonococcal infection of joint indication 44743006
Bacterial arthritis indication 48245008
Salmonella septicemia indication 49786009
Lower respiratory tract infection indication 50417007
Pneumococcal meningitis indication 51169003
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Gonococcal endocarditis indication 61048000
Acute gonococcal endometritis indication 65295003 DOID:7527
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Bacterial infection due to Serratia indication 71120004
Rhinoscleroma indication 72409005 DOID:11336
Gonorrhea of pharynx indication 74372003
Endometritis indication 78623009 DOID:1002
Bacterial meningitis indication 95883001 DOID:9470
Infection of bone indication 111253001
Staphylococcal septicemia indication 111821004
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Meningococcal meningitis indication 192644005
Escherichia coli meningitis indication 192655005
Proteus pneumonia indication 195888009
Chancroid indication 266143009 DOID:13778
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infectious disorder of joint indication 363162000
Meningitis due to Klebsiella mobilis indication 420585007
Peptostreptococcus infection indication 135341000119101
Klebsiella Pneumoniae Osteomyelitis indication
Inflammatory Disease of Female Pelvic Organs indication
Proteus Mirabilis Osteomyelitis indication
Peptostreptococcus Peritonitis indication
Enterobacter Pneumonia indication
Proteus Joint Infection indication
Haemophilus Septic Arthritis indication
Skin and Skin Structure Serratia Infection indication
E. Coli Peritonitis indication
Prevention of Perioperative Infection indication
Haemophilus Influenzae Type B Infections indication
Adult Gonococcal Conjunctivitis indication
E. Coli Septic Arthritis indication
Haemophilus Septicemia indication
Disseminated Gonococcal Infection indication
Klebsiella Pneumoniae Peritonitis indication
H. Influenzae Meningitis indication
Prevention of Meningococcal Meningitis indication
Gram-Negative Aerobic Bacillary Pneumonia indication
Skin and Skin Structure Proteus Infection indication
Haemophilus Osteomyelitis indication
Haemophilus Parainfluenzae Pneumonia indication
Enterobacter Osteomyelitis indication
Streptococcal Joint Infection indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea indication
Klebsiella Joint Infection indication
EnterobacterJoint Infection indication
Skin and Skin Structure Morganella Morganii Infection indication
Streptococcus Osteomyelitis indication
E. Coli Joint Infection indication
E. Coli Osteomyelitis indication
Pyrexia of unknown origin off-label use 7520000
Lyme disease off-label use 23502006 DOID:11729
Lyme arthritis off-label use 33937009
Pseudotuberculosis off-label use 36753006
Lyme carditis off-label use 77863005
Infection by Yersinia enterocolitica off-label use 80960004
Ventilator-acquired pneumonia off-label use 429271009
Lyme Disease of the Central Nervous System off-label use
Sexual Transmitted Disease Exposure from Sexual Assault off-label use
Disorder of gallbladder contraindication 39621005 DOID:0060262
Acute nephropathy contraindication 58574008
Hemolytic anemia contraindication 61261009 DOID:583
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.65 acidic
pKa2 4.17 acidic
pKa3 13.31 acidic
pKa4 3.29 Basic
pKa5 0.93 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D-amino-acid oxidase Enzyme IC50 5 CHEMBL
Penicillin-binding protein 2 Enzyme INHIBITOR IC50 6.21 WOMBAT-PK CHEMBL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 5.74 WOMBAT-PK CHEMBL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 6.51 WOMBAT-PK CHEMBL
Peptidoglycan synthase FtsI Enzyme INHIBITOR IC50 6.14 WOMBAT-PK CHEMBL

External reference:

IDSource
D002443 MESH_DESCRIPTOR_UI
4019667 VUID
N0000147759 NUI
C0007561 UMLSCUI
D00924 KEGG_DRUG
023Z5BR09K UNII
104376-79-6 SECONDARY_CAS_RN
4923 INN_ID
19841008 SNOMEDCT_US
4019667 VANDF
004849 NDDF
2193 RXNORM
d00052 MMSL
372670001 SNOMEDCT_US
CHEMBL161 ChEMBL_ID
9F2 PDB_CHEM_ID
DB01212 DRUGBANK_ID
CHEBI:29007 CHEBI
5326 IUPHAR_LIGAND_ID
CHEMBL1200995 ChEMBL_ID
CHEMBL3183968 ChEMBL_ID
5479530 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9678 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 14 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9768 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 14 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9856 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 14 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9857 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 14 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9858 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 14 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9859 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 14 sections
CEFTRIAXONE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3153 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 17 sections
CEFTRIAXONE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3155 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 17 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0338-5002 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 14 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0338-5003 INJECTION, SOLUTION 2 g INTRAVENOUS ANDA 14 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7332 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7333 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7334 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7335 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7336 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7337 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7338 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3206 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3207 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3208 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3209 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3210 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 21695-202 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 15 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 21695-352 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 15 sections
ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 25021-105 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 15 sections
ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 25021-106 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 15 sections
ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 25021-107 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 15 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 25021-108 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 15 sections
CEFTRIAXONE HUMAN PRESCRIPTION DRUG LABEL 1 42254-152 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 15 sections
CEFTRIAXONE HUMAN PRESCRIPTION DRUG LABEL 1 42254-191 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 15 sections